TEMECULA, Calif., March 23, 2017 -- Holy Grail Company is proud to announce the approval by FINRA for the official name change from FLEXWEEK, INC to HOLY GRAIL COMPANY, and the symbol has now changed on the OTC markets from (OTC:FXWK) to (OTC:HGRL).
|
|||
Following the announcement as of today, March 23, 2017, the name and symbol change will be effective Friday, March 24th, 2017.
“The company is very excited for the approval and could not be happier with the symbol (HGRL). We are looking forward to being in a position now to create a cash positive position for the company and allow it to exercise its branding and marketing strategies,” said Co-CEO Jason Golec, Holy Grail Company.
“It is a great feeling after all of the hard work to get us to this point. Thank you to our great team for their hard work and dedication to achieve this step,” said Co-CEO Edward Quiroz, Holy Grail Company.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Holy Grail Company actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. Holy Grail Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact Holy Grail Company forward-looking statements, please see Holy Grail Company’s filings on OTC Markets.
For more information please visit us at: www.holygrailcompany.com Phone: 866-699-5396


Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 



